Gilead said Tuesday it has leased a nearly 120,000-square-foot site in the Netherlands to support manufacture of its cancer cell therapy Yescarta, which is currently awaiting a decision on approval by EU regulators.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,